← GIP/GLP-1 & amylin agonists × cardiovascular events

TrialJournal of the American College of Cardiology2025

Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.

Milton Packer et al.PubMed ↗Publisher ↗

A later paper about NCT04847557. The trial’s primary report, PMID 39555826, speaks for it on the map; the numbers here are shown and do not vote.

  • Tirzepatidelooks good hereFewer cardiovascular death or worsening heart failure events, no clear effect on cardiovascular death or worsening heart failure events.Randomised, small.

What the trial testedrandomised · 731 people · 2025

Randomised vs placebo

Probably reduced cardiovascular death or worsening heart failure events

Doesn’t vote: a later paper about the trial

−38%−59% to −5%

tirzepatide vs placebo

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.62, 95% CI 0.41–0.95

Range includes no effect

No clear effect on cardiovascular death or worsening heart failure events

Doesn’t vote: a later paper about the trial

−36%−65% to +15%

tirzepatide vs placebo, in patients with diabetes

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.64, 95% CI 0.35–1.15

Range includes no effect

No clear effect on cardiovascular death or worsening heart failure events

Doesn’t vote: a later paper about the trial

−39%−67% to +10%

tirzepatide vs placebo, in patients without diabetes

Bigger than 8 in 10 for cardiovascular events

As reported

HR 0.61, 95% CI 0.33–1.10

Who was studied, and how

731people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

tirzepatide
placebo

Probably reduced cardiovascular death or worsening heart failure events−38%

randomised

Among patients with diabetes, the trial randomly assignedassigned by chance

tirzepatide
placebo

No clear effect on cardiovascular death or worsening heart failure events−36%

randomised

the abstract, start to end

… frequently in the tirzepatide group (HR: 0.62; 95% CI: 0.41-0.95; P = 0.026), …

… or without diabetes was similar: HR of 0.64 (95% CI: 0.35-1.15) in patients with diabetes and 0.61 (95% CI: 0.33-1.10) in patients …

← favours treatmentfavours comparator →
could be chance
Cardiovascular death or worsening heart failure eventstirzepatide vs placebo
HR 0.620.41–0.95
Cardiovascular death or worsening heart failure eventstirzepatide vs placebo, in patients with diabetes
HR 0.640.35–1.15
Cardiovascular death or worsening heart failure eventstirzepatide vs placebo, in patients without diabetes
HR 0.610.33–1.10
GIP/GLP-1 & amylin agonistsCardiovascular events
1 / 4

16 papers cite it

2025
2026
this papertrialcites it

2 trials

NCT04847557phase 3731 enrolled2021a later paper about itNCT0756737830 enrolled2026
Full record →Abstract, authors, funding and every citing paper · PMID 40903131